ISN

Stevie® Award Winners Announced in The 22nd Annual American Business Awards®

Retrieved on: 
Thursday, April 25, 2024
Lake Oswego, Oregon, TriNet, Vanguard, Georgia Dome, Innovation, Wolters Kluwer, Stevie Awards, Abas, Netcracker Technology, DHL Supply Chain, Stride, Story, Marriott Marquis, Product innovation, American Tire Distributors, Gold, RHC, 5WPR, Organization, Sale, Sunlight, VMware, Advanced Drainage Systems, ISN, IBM

FAIRFAX, Va., April 25, 2024 /PRNewswire-PRWeb/ -- The Stevie® Awards, organizers of the world's premier business awards programs, today announced the Gold, Silver, and Bronze Stevie winners in The 22nd American Business Awards®.

Key Points: 
  • FAIRFAX, Va., April 25, 2024 /PRNewswire-PRWeb/ -- The Stevie® Awards, organizers of the world's premier business awards programs, today announced the Gold, Silver, and Bronze Stevie winners in The 22nd American Business Awards®.
  • For a complete list of the Stevie Award winners announced today, visit http://www.StevieAwards.com/ABA .
  • Winners of six best-of-show prizes will be awarded Grand Stevie Award trophies, to be announced the week of April 29.
  • Sponsors of The 22nd annual American Business Awards include SoftPro, Melissa Sones Consulting, and Golden Hour.

Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024

Retrieved on: 
Thursday, April 18, 2024
Congress, CALT, UPCR, Immunoglobulin A, EGFR, Patient, Budesonide, ISN, Pharmaceutical industry

STOCKHOLM, April 18, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), today announced additional data analyses from the 2-year Phase 3 NeflgArd trial evaluating Nefecon (TARPEYO® (budesonide) delayed-release capsules/Kinpeygo®) in patients with IgA nephropathy (IgAN), were presented at the ISN World Congress of Nephrology in Buenos Aires, Argentina on April 13-16, 2024.

Key Points: 
  • STOCKHOLM, April 18, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), today announced additional data analyses from the 2-year Phase 3 NeflgArd trial evaluating Nefecon (TARPEYO® (budesonide) delayed-release capsules/Kinpeygo®) in patients with IgA nephropathy (IgAN), were presented at the ISN World Congress of Nephrology in Buenos Aires, Argentina on April 13-16, 2024.
  • "We were pleased to share additional analyses from the 2-year Phase 3 NeflgArd trial of Nefecon in IgAN at this year's World Congress of Nephrology," said Richard Philipson, Chief Medical Officer of Calliditas.
  • "These additional data further reinforce the impact of Nefecon across the entire study population, irrespective of baseline UPCR levels or patient's racial and ethnic backgrounds."
  • These findings strongly suggest preserved kidney function and provide support for Nefecon as a disease-modifying therapy in patients with IgAN.

Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024

Retrieved on: 
Thursday, April 18, 2024
Congress, CALT, UPCR, Immunoglobulin A, EGFR, Patient, Budesonide, ISN, Pharmaceutical industry

STOCKHOLM, April 18, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), today announced additional data analyses from the 2-year Phase 3 NeflgArd trial evaluating Nefecon (TARPEYO® (budesonide) delayed-release capsules/Kinpeygo®) in patients with IgA nephropathy (IgAN), were presented at the ISN World Congress of Nephrology in Buenos Aires, Argentina on April 13-16, 2024.

Key Points: 
  • STOCKHOLM, April 18, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas"), today announced additional data analyses from the 2-year Phase 3 NeflgArd trial evaluating Nefecon (TARPEYO® (budesonide) delayed-release capsules/Kinpeygo®) in patients with IgA nephropathy (IgAN), were presented at the ISN World Congress of Nephrology in Buenos Aires, Argentina on April 13-16, 2024.
  • "We were pleased to share additional analyses from the 2-year Phase 3 NeflgArd trial of Nefecon in IgAN at this year's World Congress of Nephrology," said Richard Philipson, Chief Medical Officer of Calliditas.
  • "These additional data further reinforce the impact of Nefecon across the entire study population, irrespective of baseline UPCR levels or patient's racial and ethnic backgrounds."
  • These findings strongly suggest preserved kidney function and provide support for Nefecon as a disease-modifying therapy in patients with IgAN.

Porch Group Announces Inspection Product Enhancements and Price Increases

Retrieved on: 
Tuesday, April 9, 2024
Technology, Construction & Property, Insurance, Finance, Banking, Professional Services, Software, Data Analytics, Data Management, Residential Building & Real Estate, ISN, Software as a service, Inspection

Porch Group, Inc. (“Porch” or “the Company”) (NASDAQ: PRCH), a homeowners insurance and vertical software platform, today announced product enhancements and price increases in its inspection software business.

Key Points: 
  • Porch Group, Inc. (“Porch” or “the Company”) (NASDAQ: PRCH), a homeowners insurance and vertical software platform, today announced product enhancements and price increases in its inspection software business.
  • Inspection Support Network (“ISN”) is a market-leading SaaS solution for inspectors with easy-to-use tools.
  • Along with other Porch inspection brands, together they processed approximately 40% of all U.S. home inspections in 2023.
  • ISN also has Porch’s innovative approach to rolling out new products which aim to improve its customer value proposition.

Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos Aires

Retrieved on: 
Monday, April 8, 2024
Diabetes, Anaphylaxis, IgA nephropathy, Glaucoma, CYP3A4, Dermatitis, Patient, Parasitism, Indinavir, Budesonide, Ritonavir, Quality of life, Peripheral edema, UPCR, Drug interaction, Vaccine, Saquinavir, Erythromycin, Congress, White, Risk, Headache, Spasm, Ketoconazole, Immunoglobulin A, Liver, Adrenal insufficiency, Immune system, Prediabetes, Proteinuria, Hypertension, Contraindication, Arthralgia, Ciclosporin, International Society, Immunosuppression, KOL, Acne, Infection, EGFR, Measles, Miscarriage, ISN, Hypersensitivity, Pregnancy, HPA, Chickenpox, Fetus, Birth, Itraconazole, CALT, Upper respiratory tract infection, Osteoporosis, Kidney, Cataract, Tropical ulcer, Pharmaceutical industry

The ISN World Congress of Nephrology will be held in Buenos Aires, Argentina April 13-16, 2024.

Key Points: 
  • The ISN World Congress of Nephrology will be held in Buenos Aires, Argentina April 13-16, 2024.
  • Presentations will highlight the eGFR results found in patients on Nefecon as well as the data on quality of life during the trial.
  • There will also be a presentation on the subanalysis evaluating benefits of Nefecon for patients with lower levels of UPCR.
  • The congress will include a symposium, Evolving Landscape of eFGR and Proteinuria Surrogate Markers in IgA Nephropathy, moderated by KOL Richard Lafayette, M.D., F.A.C.P.

Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos Aires

Retrieved on: 
Monday, April 8, 2024
Diabetes, Anaphylaxis, IgA nephropathy, Glaucoma, CYP3A4, Dermatitis, Patient, Parasitism, Indinavir, Budesonide, Ritonavir, Quality of life, Peripheral edema, UPCR, Drug interaction, Vaccine, Saquinavir, Erythromycin, Congress, White, Risk, Headache, Spasm, Ketoconazole, Immunoglobulin A, Liver, Adrenal insufficiency, Immune system, Prediabetes, Proteinuria, Hypertension, Contraindication, Arthralgia, Ciclosporin, International Society, Immunosuppression, KOL, Acne, Infection, EGFR, Measles, Miscarriage, ISN, Hypersensitivity, Pregnancy, HPA, Chickenpox, Fetus, Birth, Itraconazole, CALT, Upper respiratory tract infection, Osteoporosis, Kidney, Cataract, Tropical ulcer, Pharmaceutical industry

The ISN World Congress of Nephrology will be held in Buenos Aires, Argentina April 13-16, 2024.

Key Points: 
  • The ISN World Congress of Nephrology will be held in Buenos Aires, Argentina April 13-16, 2024.
  • Presentations will highlight the eGFR results found in patients on Nefecon as well as the data on quality of life during the trial.
  • There will also be a presentation on the subanalysis evaluating benefits of Nefecon for patients with lower levels of UPCR.
  • The congress will include a symposium, Evolving Landscape of eFGR and Proteinuria Surrogate Markers in IgA Nephropathy, moderated by KOL Richard Lafayette, M.D., F.A.C.P.

Unicycive Therapeutics Issues Shareholder Letter to Highlight Corporate Progress and Key Upcoming Milestones

Retrieved on: 
Tuesday, January 23, 2024
CMC, LOS, Dialysis, Patient, Therapy, International Society of Nephrology, NKF, National Kidney Foundation, ATP, Agency, Hyperphosphatemia, American Journal, Acute kidney injury, Nephrology, Clutch (eggs), ISN, Trial of the century, Society, Kidney disease, Chronic kidney disease, Water, NDA, European Renal Association, HIV/AIDS, CKD, Conditional sentence, Heart, FDA, Tablet, ERA, Letter, Patent, International Society, Mitochondrial disease, Diabetes, Physician, Pharmaceutical industry

LOS ALTOS, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today issued a letter to shareholders.

Key Points: 
  • As I sit down to write this letter, I am filled with a profound sense of gratitude and excitement, energized for the year ahead.
  • In this letter, I am pleased to recap for you another year of great accomplishments.
  • We’ve made significant advancements in our clinical programs which will propel us to new heights in 2024.
  • I would like to express my deep appreciation to the physician investigators, study participants, and especially to our dedicated Unicycive employees.

Brian Callahan Named CEO, Joe Eastin Named Executive Chairman of ISN®

Retrieved on: 
Tuesday, January 16, 2024
Aerospace, Manufacturing, Retail, Other Technology, Telecommunications, Artificial Intelligence, Human Resources, Software, Supply Chain Management, Building Systems, Luxury, Professional Services, Data Management, Technology, Construction & Property, Utilities, Oil, Gas, Energy, Other Manufacturing, Trust, Steel, Business administration, OSU, ISN, University, Oklahoma State University–Stillwater, Drink, MIT, Automotive industry, Information management, Paper, Growth, Management

Brian succeeds prior CEO Joe Eastin, who is now Executive Chairman.

Key Points: 
  • Brian succeeds prior CEO Joe Eastin, who is now Executive Chairman.
  • Joe is a remarkable person and an inspiring entrepreneur, and I want to thank him and our Board of Directors for their trust and confidence in me,” said Brian Callahan, CEO and President at ISN.
  • I am most excited about our future and am honored to continue to serve ISN as Executive Chairman.
  • I have no doubt our CEO role is in good hands with Brian Callahan,” said Joe Eastin, Executive Chairman at ISN.

De Grey Mining Selects ISNetworld for Contractor Management

Retrieved on: 
Wednesday, December 20, 2023
Technology, Human Resources, Transport, Professional Services, Business, Software, Mining, Minerals, Data Management, Logistics, Supply Chain Management, Natural Resources, ASX, CME, Mineral, ISN, Gold, Hemi, Information management, Energy, Safety, Environment

ISN , the global leader in contractor and supplier information management services, announced that De Grey Mining Ltd. (ASX: DEG) ("De Grey") has selected ISNetworld as its primary contractor information management system.

Key Points: 
  • ISN , the global leader in contractor and supplier information management services, announced that De Grey Mining Ltd. (ASX: DEG) ("De Grey") has selected ISNetworld as its primary contractor information management system.
  • ISN will assist De Grey with enhancing its contractor management process through all aspects of review and verification, contractor communication and compliance, scorecard creation, and ongoing monitoring.
  • De Grey is a Western Australian gold explorer and project developer.
  • “ISN’s global leadership in contractor management, along with its team’s local presence in Perth, made it a strong match for De Grey to partner with to move our contractor management programs forward,” said Peter Holmes, Project Director at De Grey Mining.

ISN® Releases Latest Serious Injuries and Fatalities Insights Report

Retrieved on: 
Monday, December 18, 2023
Technology, Professional Services, Mining, Minerals, Data Analytics, Natural Resources, Machinery, Other Energy, Other Manufacturing, Other Transport, Machine Tools, Metalworking & Metallurgy, Utilities, Oil, Gas, Energy, Transport, Manufacturing, Software, Human Resources, Bureau, Bureau of Labor Statistics, Safety, Employment, Organization, Public utility, Ageing, Fatality, Contact, Workforce, BLS, Amputation, Information management, Death, Interpacket gap, Total Recordable Incident Rate, Fracture, Health, COVID-19, Statistics, Tears, Anomaly, White paper, Hospital, Overalls, Injury, ISN, Construction, Risk management, Video game, Equipment, Dislocation

ISN , the global leader in contractor and supplier information management services, released its latest Serious Injuries and Fatalities (SIFs) White Paper.

Key Points: 
  • ISN , the global leader in contractor and supplier information management services, released its latest Serious Injuries and Fatalities (SIFs) White Paper.
  • The analysis of more than 127,000 recordable incidents from 2017-2022 showed nearly 24,000 SIFs cases, including more than 20,000 hospitalizations, 3,154 amputations and 871 fatalities.
  • Interestingly, the highest rate of fatalities is not correlated with the largest company size, but rather mid-size corporations.
  • While serious events are occurring, it is at a lower rate than many other industries.